Hills Bank & Trust Co. lifted its holdings in shares of Celgene Co. (NASDAQ:CELG) by 4.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,255 shares of the biopharmaceutical company’s stock after buying an additional 672 shares during the quarter. Hills Bank & Trust Co.’s holdings in Celgene were worth $1,276,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Indiana Trust & Investment Management CO acquired a new stake in shares of Celgene during the 2nd quarter worth approximately $1,307,000. Prospera Financial Services Inc acquired a new stake in shares of Celgene during the 2nd quarter worth approximately $352,000. Korea Investment CORP boosted its stake in Celgene by 1.5% during the 2nd quarter. Korea Investment CORP now owns 674,446 shares of the biopharmaceutical company’s stock worth $53,565,000 after acquiring an additional 10,000 shares during the last quarter. Headinvest LLC bought a new position in Celgene during the 2nd quarter worth approximately $1,819,000. Finally, Bangor Savings Bank boosted its stake in Celgene by 21.2% during the 3rd quarter. Bangor Savings Bank now owns 18,049 shares of the biopharmaceutical company’s stock worth $1,615,000 after acquiring an additional 3,157 shares during the last quarter. Institutional investors own 73.11% of the company’s stock.
In other Celgene news, Director Ernest Mario sold 12,000 shares of the company’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $92.32, for a total value of $1,107,840.00. Following the transaction, the director now directly owns 44,413 shares in the company, valued at $4,100,208.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John H. Weiland acquired 5,575 shares of the firm’s stock in a transaction on Tuesday, August 7th. The stock was bought at an average price of $89.73 per share, for a total transaction of $500,244.75. The disclosure for this purchase can be found here. 0.39% of the stock is owned by insiders.
Several research analysts recently weighed in on CELG shares. BidaskClub raised shares of Celgene from a “hold” rating to a “buy” rating in a research note on Thursday, August 16th. Cowen reissued a “buy” rating and set a $150.00 price objective on shares of Celgene in a research note on Tuesday, July 10th. Mizuho reissued a “buy” rating and set a $118.00 price objective on shares of Celgene in a research note on Tuesday, July 10th. Standpoint Research raised shares of Celgene from a “hold” rating to a “buy” rating in a research note on Monday, June 18th. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a research note on Thursday, October 11th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company’s stock. Celgene currently has a consensus rating of “Buy” and an average target price of $121.42.
Shares of CELG opened at $81.83 on Tuesday. The firm has a market cap of $62.94 billion, a P/E ratio of 11.96, a PEG ratio of 0.54 and a beta of 1.30. Celgene Co. has a 1-year low of $74.13 and a 1-year high of $139.72. The company has a debt-to-equity ratio of 5.76, a quick ratio of 1.40 and a current ratio of 1.52.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.05. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.70 billion. Celgene had a net margin of 19.81% and a return on equity of 87.28%. The firm’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.82 earnings per share. On average, analysts predict that Celgene Co. will post 7.64 earnings per share for the current year.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: How to use beta for portfolio diversification
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.